PharmaCorp Rx Inc. Reports Q2 2025 Financial Results

Executive Summary

• PharmaCorp RX Inc. reported financial results for the three and six months ended June 30, 2025, highlighting continued operational momentum and expansion of its pharmacy acquisition platform.
• The company reported a net loss for the quarter, attributed to investments in corporate infrastructure and the catch-up of executive compensation deferred from 2024.
• Significant subsequent events include the closing of a fourth pharmacy acquisition in Western Canada and the establishment of new credit facilities with CIBC to support further acquisitions and a pharmacist co-ownership program.

Key Details

• Financial Performance (Q2 2025):
  • Revenues generated from three operating pharmacies.
  • Same-store sales increased 11.3% year-over-year compared to Q2 2024.
  • Total prescription script count rose 3.5% year-over-year compared to Q2 2024.
  • Net loss reflects continued investment in corporate infrastructure and deferred executive compensation charges from 2024.
  • Maintained consistent weighted average EBITDA multiples across acquisitions, supporting an accretive growth model.
• Subsequent Events (Post-Q2):
  • Acquisition: Closed the acquisition of a fourth pharmacy in Western Canada on July 31, 2025.
  • Credit Facilities: Entered into a credit agreement with CIBC on August 13, 2025, providing:
    • Up to $20,500,000 in committed credit facilities.
    • A $10,000,000 accordion feature.
    • A $1,000,000 Visa credit facility.
  • Co-Ownership Program: CIBC provided a separate $5,000,000 credit facility to support the Pharmacist Co-Ownership Program, enabling loans to pharmacists wishing to acquire ownership positions in PharmaCorp pharmacies.
• Operational Updates:
  • Successfully deployed operating infrastructure for national scalability, including systems integration and pharmacy onboarding.
  • Strong balance sheet positions the company to fund additional acquisitions already under letter of intent.
  • Actively finalizing definitive purchase and sale agreements for previously announced letters of intent (from May 29, 2025), with expectations to close additional transactions in the second half of the year.

Notable Quotes

• “We are pleased with the momentum we’re seeing across our early acquisitions and the continued appetite from independent pharmacy owners exploring succession... This quarter reflects continued progress in scaling our platform through disciplined execution.” — Alan Simpson, Executive Chairman